SciSparc Ltd. shares surge as investors react to its most impactful biotech news, with stocks have been trading up by 35.54 percent
Click Here for a Millionaire's POV on Trading SPRC
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Majority-owned unit NeuroThera filed three new U.S. patent applications pairing PEA tech with LSD, ketamine and ibogaine for depression, PTSD, pain and substance use disorders.
- Partnership activity expanded SPRC’s U.S. patent portfolio around psychedelic plus N‑acylethanolamine combinations, including proprietary palmitoylethanolamide, for central nervous system and pain indications.
- CliniQuantum, under NeuroThera, used a GPU‑accelerated quantum platform to scan billions of three‑gene combinations from real clinical data with roughly 16.8x faster performance than CPU‑only tests.
- The quantum benchmark validates SPRC’s computational firepower but offers no proven clinical utility or direct revenue impact yet, keeping it an early‑stage, speculative growth story for traders.
Live Update At 07:48:14 EDT: On Thursday, October 15, 2026 SciSparc Ltd. stock [NASDAQ: SPRC] is trending up by 35.54%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
SciSparc Ltd. (SPRC) trades like a classic low‑priced, speculative biotech. Over the last few weeks, SPRC has slipped from the mid‑$5s to the mid‑$3s, with the latest close near $3.63 after a steady series of lower highs. That tells traders momentum has cooled and dip buyers have not yet taken control again.
On the fundamentals side, SPRC posted about $856,000 in revenue, but the core story is not current sales. With a price‑to‑sales ratio around 3.03, the market is paying a moderate premium for a tiny revenue base and a large research pipeline. Book value per share sits near $7.30, while SPRC trades well below that level, around half of stated book. For value‑oriented traders, that gap stands out, but negative returns on capital near ‑67% highlight that the company is still burning resources to build its platform.
More Breaking News
- NBIS Stock Slides As Bearish Momentum And Burry Puts Pile Up
- TSM Stock Pulls Back As Traders Eye Key Support
- BMNR Stock Slides As Traders Weigh Deep Losses And Cash War Chest
- Beam Global BEEM Stock In Focus After $24M ScoutDI Drone Deal
The balance sheet shows roughly $4.6M in cash and short‑term investments versus about $2.3M in current liabilities, giving SPRC working capital of around $3.18M. Leverage is modest, with total liabilities far below equity. For traders, that means SPRC has some runway to keep pushing its psychedelic and quantum initiatives, but dilution risk always hangs over small‑cap biotech names. The tape and the cash stack both argue for nimble, risk‑managed trading, not blind conviction.
Why Traders Are Watching SPRC’s Psychedelic And Quantum Moves
SPRC has one thing momentum traders crave: a real story. Through its majority‑owned subsidiary NeuroThera, SciSparc just pushed out three new U.S. patent applications that pair its palmitoylethanolamide (PEA) technology with major psychedelic compounds like LSD, ketamine and ibogaine. The targets are heavyweight conditions — depression, PTSD, chronic pain and substance use disorders. That gives SPRC a wide map of potential catalysts if any of these programs advance.
At the same time, SciSparc’s NeuroThera Labs unit, alongside partner Clearmind Medicine, expanded the U.S. IP portfolio again with three patent applications focused on combinations of psychedelics and N‑acylethanolamines, including the same proprietary PEA backbone. This dual‑track IP push tells traders that SPRC is not betting on a single drug. It is trying to build a platform around psychedelic‑based therapies for central nervous system and pain indications.
Then comes the tech angle. CliniQuantum, another NeuroThera subsidiary, benchmarked a GPU‑accelerated quantum‑simulation platform that crunched billions of three‑gene combinations from real‑world clinical data. The system clocked about a 16.8x speedup versus CPU‑only runs on an S&P 500 company’s cloud‑based quantum architecture. For SPRC, that is a credibility win in computational biology.
Still, traders need to stay realistic. None of this news confirms a working drug, regulatory approval, or revenue spike. SPRC is stacking intellectual property, data tools and optionality. That is classic early‑stage biotech territory — big stories, long timelines and volatile charts that reward discipline more than dreams.
Conclusion
SPRC now sits at the intersection of three hot themes: psychedelics, pain and CNS disorders, and advanced computational drug discovery. The steady stream of U.S. patent applications from NeuroThera and NeuroThera Labs, plus the collaboration with Clearmind Medicine, shows SciSparc Ltd. is serious about locking down intellectual property around its PEA‑psychedelic combinations. Add CliniQuantum’s quantum‑enhanced analysis benchmark, and SPRC looks like a company trying to future‑proof its R&D toolkit.
For traders, none of that removes risk. SPRC still runs a small revenue line, negative returns on capital and a share price sliding from the $5 area to the mid‑$3s. Any misstep, financing headline or quieter news cycle can send the stock lower. On the flip side, a single strong update around these patents, a licensing deal, or progress using the quantum‑simulation platform could light up the tape fast.
This is why SPRC belongs on watchlists, not on autopilot. As Tim Sykes loves to remind traders, “Patterns repeat, but only for those who study relentlessly and cut losses quickly.” That mindset aligns closely with the prep‑focused approach many day traders follow: scan, plan, and only then execute. As Tim Bohen, lead trainer with StocksToTrade says, “Preparation is half the trade. By the time the bell rings, my decisions are nearly made.” SPRC fits that playbook: speculative biotech, clear catalysts, heavy volatility. Study the chart, track every press release, and treat SPRC as an educational case in how news, IP and technology align to create trading opportunity — never as a guarantee of future returns. This content is strictly for educational and research purposes, not trading advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.